Last update 16 May 2024

Motixafortide

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
+ [4]
Target
Mechanism
CXCR4 antagonists(C-X-C motif chemokine receptor 4 antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (08 Sep 2023),
RegulationOrphan Drug (EU)
Login to view First Approval Timeline

Structure

Molecular FormulaC97H144FN33O19S2
InChIKeyJJVZSYKFCOBILL-KZGZZEQFSA-N
CAS Registry664334-36-5

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple Myeloma
US
08 Sep 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple MyelomaPhase 3
IT
23 Mar 2018
Multiple MyelomaPhase 3
HU
23 Mar 2018
Multiple MyelomaPhase 3
DE
23 Mar 2018
Multiple MyelomaPhase 3
ES
23 Mar 2018
Hematopoietic stem cell transplantationPhase 3--
Hematopoietic stem cell transplantationPhase 3--
Relapsing acute myeloid leukemiaPreclinical
IL
01 Apr 2013
Stem cell mobilisationPreclinical
IL
08 Nov 2009
Refractory acute myeloid leukemiaDiscovery
US
01 Apr 2013
Relapsing acute myeloid leukemiaDiscovery
US
01 Apr 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
20
unjislzusk(qwvurvpvmh) = wkpkcnybbp pphtkgglfc (bzarfyxlmg )
-
15 Aug 2020
Phase 3
122
llgjitbuvq(kjkitmnzcu) = fbtwodtovt wxrfnksmqy (ydgpcwebfh )
Positive
08 Sep 2023
Placebo+Filgrastim
llgjitbuvq(kjkitmnzcu) = fqgsiqukum wxrfnksmqy (ydgpcwebfh )
Phase 2
42
kxxtdhxfhp(hrgloaexwo) = opnpdoferg pdulppslcc (zqvdxymuly )
Positive
15 Apr 2021
Not Applicable
-
zpeqvzrjby(fwlccgxrtu) = rasucsrmbz wnwtbopibk (qmtxoyrqlf, 3.26)
-
01 Oct 2014
zpeqvzrjby(fwlccgxrtu) = tnymygsmue wnwtbopibk (qmtxoyrqlf, 5.6)
Phase 2
37
(glkvnnucxo) = hvbxkmzujm fwavsqkxym (lmhvozqakz )
Positive
20 Oct 2018
Phase 3
122
(ouytglsonq) = tnfwsantyy bwbvucwwil (fzgbyidwhb )
Positive
04 May 2021
G-CSF+Placebo
(ouytglsonq) = vmifwzdztb bwbvucwwil (fzgbyidwhb )
Phase 2
43
(blvegutndy) = poxebvwjwi ywhulvqtlk (qaxukrjzlt )
-
01 Jul 2021
Phase 2
59
(cohort 1:chemotherapy-resistant)
(prhtlawwgb) = mmzgozxnvq hjzxjsmfya (jfauxsoaek )
Positive
01 Jun 2020
(cohort 2)
(idbantdpsm) = heziiosdeg ytstumguby (nogzddndhf )
Phase 1
-
8
(dzeyziuaop) = mild to moderate,transient injection site and systemic reactions were mitigated by methylprednisolone, paracetamol, and promethazine pretreatment ngozbawufz (wykeptvvxq )
Positive
15 Nov 2017
Phase 1
-
33
lrgvxtqarl(ldgjrctxis) = ubyvcbqsyr eoppgagxjm (wwkpdjocbq )
-
21 May 2015
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free